The Venture Leaders Biotech 2022 kick-off their roadshow to Boston and Cambridge
In September, the ten Venture Leaders Biotech 2022 will represent Switzerland and pitch their solutions in Boston, USA. During their weeklong roadshow, the entrepreneurs will meet with investors, experts, and industry leaders to strengthen their network and advance their global growth. To introduce themselves and their startups, the founders met in Zurich and showcased their innovations at an online pitch session.
During the virtual event on August 18th, the Venture Leaders Biotech 2022 learned more about each other’s innovations, talked about their startup journeys thus far, and pitched their unique biotech solutions. Audience members then voted for the team captain and selected Ana Montalban-Arques, CEO of Recolony, for the title.
The Venture Leaders— as members of the Swiss National Startup Team— have a clear-cut goal: They envision themselves as global players and want to fuel their international expansion. The ten entrepreneurs of this year’s selection had the opportunity to practice their pitches for their promising biotech projects in front of an audience and one another. The Investor and Business Development Roadshow to the Boston area will allow for a deep dive into the global biotech scene. It will include public and private pitch sessions, high-level networking opportunities, company visits, and individual business development activities.
“The Venture Leaders roadshow for biotech startups will highlight the remarkable Swiss innovations taking place in this sector. Our goal is to nurture connections and investment opportunities for these startups so that their ideas and projects can realize their maximum potential,” said Jordi Montserrat, managing partner at Venturelab. “The Venture Leaders Biotech startups 2022 are highly impressive, and I am sure they will leave Boston with additional resources to support their important work.”
Venturelab has been organizing international roadshows for the Swiss National Startup Teams for 17 years. The ambitious entrepreneurs and their promising startups are introduced to top-class investors and potential customers in leading technology hubs such as Silicon Valley, Boston, New York, London, Munich, Shanghai, Beijing, Shenzhen, and Barcelona.
The Venture Leaders Biotech program is co-organized by Venturelab and Swissnex Boston and supported by Debiopharm, EPFL Lausanne, ETH Zurich, EY - Ernst & Young, Swiss Biotech Association, VISCHER, Hansjörg Wyss, and Venture Leaders alum Ulf Grawunder.
Follow the entrepreneurs and the Venture Leaders Medtech roadshow on social media by using the hashtag #VLeadersBiotech on Twitter or on www.venturelab.swiss/biotech.
Learn more about the Venture Leaders Biotech 2022:
Adularia AG: Precision Cancer Immunotherapy
At Adularia, our technology is rooted in the discovery of a potent immune mechanism, which is based on insights from the symbiotic interplay between gut microbes and the immune system. We have identif... Read more
Alentis Therapeutics AG: Developing Claudin-1 antibodies for cancer and fibrosis
Alentis Therapeutics, the Claudin-1 company, is a clinical-stage biotech developing breakthrough treatments for Claudin-1 positive tumors and organ fibrosis. Alentis is the only company pioneering a n... Read more
Bionomous SA: Devices for the automatic sorting of miniature entities
Bionomous aims at bringing to the market new solutions that combines innovative micro-engineering design and machine learning methods to automatically count, screen, sort and dispense miniature biolog... Read more
Bionter AG: Revolutionize analytical testing to benefit people's health
Our first in the first family of tailored solutions for the Drug Product sector: the EVE particle counter. The revolutionary analytical testing device, supported with single-use consumables, maintena... Read more
FimmCyte AG: First Disease Modifying Treatment for Endometriosis
One in 10 women suffer from Endometriosis: a painful, chronic, infertility causing and recurrent disease. Endometriosis has a physical health burden comparable to cancer, yet only one new treatment wa... Read more
Healiva SA: Healiva redefines skincare through personalized solutions
Healiva is a patient-centric Biotech commercialising a portfolio of innovative, personalised and affordable life-enhancing precision medicine for chronic and acute wounds and target key pain-points in... Read more
InCephalo AG: Next generation drug delivery for almost any drug modality
InCephalo is a preclinical stage biotech company founded in May 2021. InCephalo's six (6) founders with various backgrounds came together with the vision of making a difference in the lives of those b... Read more
lino Biotech AG: Discover Molecular interactions
lino Biotech is the world´s only provider of Focal Molography an entirely new method for measuring molecular interactions in living cells or crude biological samples. The broadly patented technology... Read more
Vanarix SA: Allogeneic Cartilage bio-implants ready for phase III
Vanarix offers off the shelf Cartibeads™ — allogeneic 3D cultured cartilage bio-implants to repair large knee defects. • FDA orphan designation for osteochondritis dissecans. Key milestones achieved ... Read more
Related articles
Swiss National Startup Team 2023: 10 biotech innovators are headed to Boston
read more
lino Biotech acquired by Miltenyi Biotec
read more
Bionomous secures USD 2.7 million for the deployment of its automatic screening device
read more
Venture Leaders Biotech 2022: Captain’s blog by Recolony CEO Ana Montalban-Arques
read more
The Venture Leaders Biotech impress international investors and industry leaders in Boston
read more
Vanarix: The Venture Leader Biotech regenerating tissue to treat cartilage damage
read more
Recolony: The Venture Leader Biotech developing bacteria-based therapy to treat cancer
read more
InterAx: The Venture Leader Biotech advancing drug discovery programs
read more
lino Biotech: The Venture Leader Biotech making cell therapies cost effective and accessible
read more
Healiva: The Venture Leader Biotech offering end-to-end wound care solutions
read more
InCephalo: The Venture Leader Biotech overcoming the limitations of brain cancer therapy
read more
Bionter: The Venture Leader Biotech revolutionizing analytical testing to improve healthcare
read more
Alentis Therapeutics: The Venture Leader Biotech developing breakthrough treatments for rare diseases and cancers
read more
FimmCyte: The Venture Leader Biotech developing the first disease-modifying treatment for endometriosis
read more